Locations:
Search IconSearch

Research

19-NEU-020-Neuro-2018
January 11, 2019/Neurosciences/Research

10 Standout Neurological Studies from 2018

And why they matter, in the words of their investigators

18-NEU-5956-Epilepsy-Biobank
January 8, 2019/Genomic Medicine

Banking Biospecimens to Get at Genetic Risks for Seizure Recurrence After Epilepsy Surgery

Pilot study explores genetic underpinnings of late seizure recurrence

18-NEU-5864_glioblastoma-sex-differences_650x450

Sex Differences Loom Large in Glioblastoma Development

Understanding the role of patient sex may lead to personalized therapies

18-NEU-5870-Mohammadi-CQD
December 14, 2018/Cancer

Laser Ablation May Be Better Than Biopsy Alone for Newly Diagnosed Deep-Seated Glioblastoma

Extent of ablated tumor coverage is a significant prognostic factor

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

18-NEU-5853-MRfingerprinting-Hero-650×450
December 2, 2018/Neurosciences/Research

Novel Brain MRI Techniques to Improve Epilepsy Surgery: Updates from AES 2018

Studies yield promising data in patients undergoing presurgical evaluation

18-NEU-5687-myelocortical-multiple-sclerosis-650×450

Myelocortical Multiple Sclerosis: Neurodegeneration Without White Matter Demyelination

Discovery of new MS subtype suggests that the axon itself may be primary site of injury

18-NEU-5744-MS-Therapy-650×450
November 12, 2018/Neurosciences/Research

Disease-Modifying Therapy for MS: Discontinuing After Age 60 Appears Safe

Observational study suggests age may be a better guide than disease stability

18-NEU-4915_650x450-glioblastoma

Taking on Glioblastoma Through Translational Research: 4 Promising Bench-to-Bedside Initiatives

Rationale and status reports on mechanistically diverse strategies

18-NEU-Alzheimers-Brain-650×450

Funding Award Enables First Study to Examine Cognitive Effects of an Alpha-1 Agonist

Cleveland Clinic-developed “compound 3” begins testing in preclinical Alzheimer’s model

BackPage 10 of 23Next

Advertisement

Ad